InDex Pharmaceuticals Holding AB (publ)

OM:INDEX Stock Report

Market Cap: SEK 286.6m

This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

InDex Pharmaceuticals Holding Past Earnings Performance

Past criteria checks 0/6

InDex Pharmaceuticals Holding has been growing earnings at an average annual rate of 2.7%, while the Pharmaceuticals industry saw earnings growing at 8.4% annually. Revenues have been growing at an average rate of 89.5% per year.

Key information

2.7%

Earnings growth rate

53.7%

EPS growth rate

Pharmaceuticals Industry Growth30.5%
Revenue growth rate89.5%
Return on equity-23.9%
Net Margin-52.1%
Next Earnings Update20 Aug 2024

Recent past performance updates

Recent updates

Market Might Still Lack Some Conviction On InDex Pharmaceuticals Holding AB (publ) (STO:INDEX) Even After 35% Share Price Boost

Jun 13
Market Might Still Lack Some Conviction On InDex Pharmaceuticals Holding AB (publ) (STO:INDEX) Even After 35% Share Price Boost

Further Upside For InDex Pharmaceuticals Holding AB (publ) (STO:INDEX) Shares Could Introduce Price Risks After 26% Bounce

Apr 28
Further Upside For InDex Pharmaceuticals Holding AB (publ) (STO:INDEX) Shares Could Introduce Price Risks After 26% Bounce

We're Keeping An Eye On InDex Pharmaceuticals Holding's (STO:INDEX) Cash Burn Rate

Jul 11
We're Keeping An Eye On InDex Pharmaceuticals Holding's (STO:INDEX) Cash Burn Rate

We Think InDex Pharmaceuticals Holding (STO:INDEX) Can Afford To Drive Business Growth

Jan 21
We Think InDex Pharmaceuticals Holding (STO:INDEX) Can Afford To Drive Business Growth

We Think InDex Pharmaceuticals Holding (STO:INDEX) Can Afford To Drive Business Growth

Aug 31
We Think InDex Pharmaceuticals Holding (STO:INDEX) Can Afford To Drive Business Growth

Here's Why We're Watching InDex Pharmaceuticals Holding's (STO:INDEX) Cash Burn Situation

Mar 29
Here's Why We're Watching InDex Pharmaceuticals Holding's (STO:INDEX) Cash Burn Situation

InDex Pharmaceuticals Holding's (STO:INDEX) Shareholders Are Down 24% On Their Investment Over The Past Year.

Feb 04
InDex Pharmaceuticals Holding's (STO:INDEX) Shareholders Are Down 24% On Their Investment Over The Past Year.

How Much Are InDex Pharmaceuticals Holding AB (publ) (STO:INDEX) Insiders Spending On Buying Shares?

Dec 21
How Much Are InDex Pharmaceuticals Holding AB (publ) (STO:INDEX) Insiders Spending On Buying Shares?

Revenue & Expenses Breakdown

How InDex Pharmaceuticals Holding makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

OM:INDEX Revenue, expenses and earnings (SEK Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Mar 24108-561710
31 Dec 2398-951880
30 Sep 2398-461430
30 Jun 2398-121340
31 Mar 231-1231560
31 Dec 221-1001400
30 Sep 22-2-671230
30 Jun 22-2-921270
31 Mar 220-1131170
31 Dec 210-1031000
30 Sep 213-90860
30 Jun 213-70590
31 Mar 210-43350
31 Dec 200-57410
30 Sep 200-73530
30 Jun 200-92730
31 Mar 200-95800
31 Dec 190-88830
30 Sep 190-84830
30 Jun 190-72710
31 Mar 190-81800
31 Dec 181-82810
30 Sep 180-82820
30 Jun 180-80800
31 Mar 180-69690
31 Dec 170-73630
30 Sep 170-67540
30 Jun 170-61480
31 Mar 170-56410
31 Dec 160-41340
30 Sep 160-31280
30 Jun 160-31290
31 Mar 160-29280
31 Dec 150-30280
30 Sep 150-33300
30 Jun 150-36320
31 Mar 1523-25420
31 Dec 1445-15520
31 Dec 131-68620

Quality Earnings: INDEX is currently unprofitable.

Growing Profit Margin: INDEX is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: INDEX is unprofitable, but has reduced losses over the past 5 years at a rate of 2.7% per year.

Accelerating Growth: Unable to compare INDEX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: INDEX is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (1.1%).


Return on Equity

High ROE: INDEX has a negative Return on Equity (-23.93%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/06/10 08:30
End of Day Share Price 2024/06/10 00:00
Earnings2024/03/31
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

InDex Pharmaceuticals Holding AB (publ) is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Arvid NecanderCarnegie Investment Bank AB
Filip EinarssonRedeye